Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Nov
06
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo